SF3B1 and cancer: For instance, the recurrent mutation in splicing factors such as SRSF2, U2AF1, ZRSR2, or SF3B1 in myelodysplastic syndrome is associated with a more significant reduction in cancer cell numbers in response to PRMT5 inhibition [164,167].